Growing Use of Biosimilar in treating IBD; Efficacy and Cost-effectiveness to be Major Demand Drivers
Albany, US, 2018-Oct-30 — /EPR Network/ —Inflammatory bowel disease (IBD) is an idiopathic inflammatory disease of the gastrointestinal system which is chronic in nature. The [read full press release…]